- Event featuring renowned myelofibrosis expert
Dr. Ruben Mesa scheduled for
7:00 am ET on December 8th -
- Data highlighting decreased transfusion
requirements for patients treated with momelotinib directly
compared to ruxolitinib to be reported in a poster at ASH -
VANCOUVER, Dec. 2, 2019 /CNW/ - Sierra Oncology, Inc.
(Nasdaq: SRRA), a late-stage drug development company focused on
the development and commercialization of momelotinib, a JAK1, JAK2
& ACVR1 inhibitor with a potentially differentiated therapeutic
profile for the treatment of myelofibrosis, today announced that it
will host an Analyst & Investor Event on Sunday, December 8th at 7:00 am ET to discuss newly reported clinical
data for momelotinib that will be presented at the 61st American
Society of Hematology (ASH) Annual Meeting in Orlando, Florida.
The event will be led by Dr. Nick
Glover, President and CEO of Sierra Oncology, and will
include a presentation by renowned myelofibrosis expert, Dr.
Ruben Mesa, Director of the Mays
Cancer Center, home to UT Health San Antonio MD Anderson Cancer
Center. Dr. Mesa and members of Sierra Oncology's senior management
team will be available to answer questions at the conclusion of the
event.
New analyses of RBC transfusion data from SIMPLIFY-1, a
double-blind Phase 3 trial of Sierra's investigational drug
momelotinib head-to-head versus ruxolitinib in JAK inhibitor naïve
patients, will be presented in a poster by Dr. Mesa on Saturday, December 7th at the ASH
Annual Meeting. These analyses demonstrate that patients who
received momelotinib had significantly decreased transfusion
requirements compared to those treated with ruxolitinib, including
a nearly 10-fold higher odds of receiving no transfusions during
the 24-week study period.
Analyst and Investor Event and Webcast
Information
Date and Time: Sunday,
December 8th at 7:00 – 8:00 am ET
Location: Bayhill 33 Meeting Room, Hyatt Regency, 9801
International Dr., Orlando
Event registration and webcast information are available through
the Sierra Oncology website at www.sierraoncology.com. The event
will be webcast live, and an archive of the presentation will be
accessible after the event through the Sierra Oncology website.
ASH 2019 Momelotinib Poster Presentation
Information:
Title: Dynamic and Time-To-Event Analyses
Demonstrate Marked Reduction in Transfusion Requirements for Janus
Kinase Inhibitor–Naïve Myelofibrosis Patients Treated with
Momelotinib Compared Head to Head with Ruxolitinib
Session Name: 634. Myeloproliferative Syndromes: Clinical: Poster
I
Date: Saturday, December
7th, 2019
Presentation Time: 5:30 pm - 7:30 pm
ET
Location: Orange County Convention
Center, Hall B
The poster will be available on Saturday,
December 7th, 2019 on the company's website at
www.sierraoncology.com
About Sierra Oncology
Sierra Oncology is a late stage
drug development company focused on advancing targeted therapeutics
for the treatment of patients with significant unmet medical needs
in hematology and oncology.
Momelotinib, Sierra's lead drug candidate, is a potent,
selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor
with a differentiated therapeutic profile in myelofibrosis
encompassing robust constitutional symptom improvements, a range of
meaningful anemia benefits, including eliminating or reducing the
need for frequent blood transfusions, and comparable spleen control
to ruxolitinib. More than 1,200 subjects have received momelotinib
since clinical studies began in 2009, including more than 800
patients treated for myelofibrosis. Sierra recently launched the
MOMENTUM Phase 3 clinical trial, a randomized double-blind trial
designed to enroll 180 myelofibrosis patients who are symptomatic
and anemic, and who have been treated previously with a JAK
inhibitor.
The U.S. Food and Drug Administration has granted Fast Track
designation to momelotinib for the treatment of patients with
intermediate/high-risk myelofibrosis who have previously received a
JAK inhibitor. Momelotinib is wholly owned by Sierra Oncology and
is protected by patents anticipated to provide potential
exclusivity to 2040 in the United
States and Europe
(including Patent Term Extension or Supplementary Protection
Certificate).
Sierra is also developing a portfolio of DNA Damage Response
(DDR) assets, consisting of SRA737 and SRA141, and is conducting a
campaign intended to seek non-dilutive strategic options to support
their further advancement. SRA737 is a potent, highly selective,
orally bioavailable small molecule inhibitor of Checkpoint kinase 1
(Chk1), a key regulator of cell cycle progression and the DDR
network, and has demonstrated preliminary clinical efficacy. SRA141
is a potent, selective, orally bioavailable small molecule
inhibitor of Cell division cycle 7 kinase (Cdc7) with a potential
novel mechanism of cytotoxicity, and has successfully completed the
IND process with the FDA enabling the commencement of clinical
trials. Sierra retains the global commercialization rights to
SRA737 and SRA141.
For more information, please visit www.sierraoncology.com.
Cautionary Note on Forward-Looking Statements
This
press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, including, but not limited to,
statements regarding Sierra Oncology's expectations from current
data, anticipated clinical development activities, the expected
timing of, and results of MOMENTUM, potential benefits of Sierra
Oncology's lead product candidate and other product candidates and
sufficiency of its capital resources. All statements other than
statements of historical fact are statements that could be deemed
forward-looking statements. These statements are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and assumptions that could cause
actual results to differ materially from those described in the
forward-looking statements. Such forward-looking statements are
subject to risks and uncertainties, including, among others, the
risk that Sierra Oncology may be unable to successfully develop and
commercialize product candidates, product candidates may not
demonstrate safety and efficacy or otherwise produce positive
results, Sierra Oncology may experience delays in the preclinical
and anticipated clinical development of its product candidates,
Sierra Oncology may be unable to acquire additional assets to build
a pipeline of additional product candidates, Sierra Oncology's
third-party manufacturers may cause its supply of materials to
become limited or interrupted or fail to be of satisfactory
quantity or quality, Sierra Oncology's cash resources may be
insufficient to fund its current operating plans and it may be
unable to raise additional capital when needed, Sierra Oncology may
be unable to obtain and enforce intellectual property protection
for its technologies and product candidates and the other factors
described under the heading "Risk Factors" set forth in Sierra
Oncology's filings with the Securities and Exchange Commission from
time to time. Sierra Oncology undertakes no obligation to update
the forward-looking statements contained herein or to reflect
events or circumstances occurring after the date hereof, other than
as may be required by applicable law.
View original
content:http://www.prnewswire.com/news-releases/sierra-oncology-announces-investor-event-to-discuss-momelotinib-data-being-reported-at-ash-300967176.html
SOURCE Sierra Oncology